Loading
A phase 2 trial of Darolutamide in prostate cancer, run by Bayer, now recruiting.
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer. is a phase 2 interventional study registered as NCT07450599 by Bayer, with 250 participants planned, started 2026-04-27 and due to reach its primary completion in 2028-10-15. Interventions recorded: Darolutamide, ADT. Conditions listed: High-risk Localized Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Darolutamide, Bayer, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Bayer, Androgen deprivation & AR pathway inhibitors.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Prostate cancer.
Shares Localised prostate cancer, high and very high risk, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Darolutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.